Turn Biotechnologies, Inc. is a Silicon Valley-based development-stage company focused on the repair of tissue at the cellular level. Turn’s Stanford-licensed and patent-pending mRNA platform technologies combat the effects of agi...
See More ng in the epigenome, thus restoring optimal gene expression and enabling cells to function as vigorously as younger cells. Our transient epigenetic reprogramming technology has the potential to significantly impact a wide variety of age-related diseases, and we are currently exploring treatments for dermatological, respiratory, and osteoarthritic conditions.